Global connectivity of hub residues in Oncoprotein structures encodes genetic factors dictating personalized drug response to targeted Cancer therapy

Venky Soundararajan; Murali Aravamudan

doi:10.1038/srep07294

journal article Open Access Dec 03, 2014

Global connectivity of hub residues in Oncoprotein structures encodes genetic factors dictating personalized drug response to targeted Cancer therapy

Venky Soundararajan Murali Aravamudan

Scientific Reports Vol. 4 No. 1 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/srep07294

Topics

No keywords indexed for this article. Browse by subject →

References

47

[1]

Ringe, D. & Petsko, G. How Enzymes Work. Science 320, 1428–29 (2008). 10.1126/science.1159747

[2]

Calculation of Protein-Ligand Binding Affinities

Michael K. Gilson, Huan-Xiang Zhou

Annual Review of Biophysics and Biomolecular Struc... 2007 10.1146/annurev.biophys.36.040306.132550

[3]

Ciulli, A., Williams, G., Smith, A. G., Blundell, T. L. & Abell, C. Probing Hot Spots at Protein-Ligand Binding Sites: A Fragment-Based Approach Using Biophysical Methods. J. Med. Chem. 49, 4992–5000 (2006). 10.1021/jm060490r

[4]

Singh, N. & Warshel, A. Absolute binding free energy calculations: On the accuracy of computational scoring of protein–ligand interactions. Prot: Struct, Func and Bioinfo. 78, 1705–1723 (2010).

[5]

Huang, D., Lafleur, K., Nevado, C. & Caflisch, A. Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis. Bioinformatics 26, 198–204 (2010). 10.1093/bioinformatics/btp650

[6]

Szilágyi, A., Nussinov, R. & Csermely, P. Allo-network drugs: extension of the allosteric drug concept to protein- protein interaction and signaling networks. Curr Top Med Chem. 13, 64–77 (2013). 10.2174/1568026611313010007

[7]

Allostery and cooperativity revisited

Qiang Cui, Martin Karplus

Protein Science 2008 10.1110/ps.03259908

[8]

Allosteric Mechanisms of Signal Transduction

Jean-Pierre Changeux, STUART J. EDELSTEIN

Science 2005 10.1126/science.1108595

[9]

Evolutionarily conserved networks of residues mediate allosteric communication in proteins

Gürol M. Süel, Steve W. Lockless, Mark A. Wall et al.

Nature Structural Biology 2002 10.1038/nsb881

[10]

Molecular signatures of G-protein-coupled receptors

A. J. Venkatakrishnan, Xavier Deupi, Guillaume Lebon et al.

Nature 2013 10.1038/nature11896

[11]

Structure-based model of allostery predicts coupling between distant sites

Patrick Weinkam, Jaume Pons, Andrej Šali

Proceedings of the National Academy of Sciences 2012 10.1073/pnas.1116274109

[12]

Cheng, T. M. K., Lu, Y.-E., Vendruscolo, M., Lio, P. & Blundell, T. L. Prediction by Graph Theoretic Measures of Structural Effects in Proteins Arising from Non-Synonymous Single Nucleotide Polymorphisms. PLoS Comput Biol. 4, e1000135 (2008). 10.1371/journal.pcbi.1000135

[13]

Can Morphing Methods Predict Intermediate Structures?

Dahlia R. Weiss, Michael Levitt

Journal of Molecular Biology 2009 10.1016/j.jmb.2008.10.064

[14]

Direct-coupling analysis of residue coevolution captures native contacts across many protein families

Faruck Morcos, Andrea Pagnani, Bryan Lunt et al.

Proceedings of the National Academy of Sciences 2011 10.1073/pnas.1111471108

[15]

PROTEIN STRUCTURE: INSIGHTS FROM GRAPH THEORY

Saraswathi Vishveshwara, K. V. BRINDA, N. KANNAN

Journal of Theoretical and Computational Chemistry 2002 10.1142/s0219633602000117

[16]

Soundararajan, V. et al. Networks link antigenic & receptor-binding sites of influenza hemagglutinin: Mechanistic insight into fitter strain propagation. Sci. Rep. 1, 200 (2011). 10.1038/srep00200

[17]

Shan, Y., Arkhipov, A., Kim, E. T., Pan, A. C. & Shaw, D. E. Transitions to catalytically inactive conformations in EGFR kinase. Transitions to catalytically inactive conformations in EGFR kinase. Proc. Nat. Acad. Sci. 110, 7270–7275 (2014). 10.1073/pnas.1220843110

[18]

Activation pathway of Src kinase reveals intermediate states as targets for drug design

Diwakar Shukla, Yilin Meng, Benoît Roux et al.

Nature Communications 2014 10.1038/ncomms4397

[19]

Ghosh, A., Vishveshwara, S. Variations in Clique and Community Patterns in Protein Structures during Allosteric Communication: Investigation of Dynamically Equilibrated Structures of Methionyl tRNA Synthetase Complexes. Biochem J. 47, 11398–11407 (2008). 10.1021/bi8007559

[20]

Shrager, J. & Tenenbaum, J. M. Rapid learning for precision oncology. Nat Rev Clin Oncol. 11, 109–118 (2014). 10.1038/nrclinonc.2013.244

[21]

Hu, R., Wang, X. & Zhan, X. Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer. EPMA J. 4, 2 (2013). 10.1186/1878-5085-4-2

[22]

The anatomy of a large-scale hypertextual Web search engine

Sergey Brin, Lawrence Page

Computer Networks and ISDN Systems 1998 10.1016/s0169-7552(98)00110-x

[23]

Langville, A. & Meyer, C. Google's Page Rank and Beyond: The Science of Search Engine Rankings (Princeton University Press, New Jersey, 2006). 10.1515/9781400830329

[24]

Lead identification of novel and selective TYK2 inhibitors

Jun Liang, Vickie Tsui, Anne Van Abbema et al.

European Journal of Medicinal Chemistry 2013 10.1016/j.ejmech.2013.03.070

[25]

Argiriadi, M. A. et al. Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor. BMC Struct Biol. 12, 22 (2012). 10.1186/1472-6807-12-22

[26]

Chrencik, J. E. et al. Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6. J. Mol. Biol. 400, 413–433 (2010). 10.1016/j.jmb.2010.05.020

[27]

Yang, J. et al. A Conserved Glu–Arg Salt Bridge Connects Coevolved Motifs That Define the Eukaryotic Protein Kinase Fold. J. Mol. Biol. 415, 666–679 (2012). 10.1016/j.jmb.2011.11.035

[28]

Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors

Michele McTigue, Brion William Murray, Jeffrey H. Chen et al.

Proceedings of the National Academy of Sciences 2012 10.1073/pnas.1207759109

[29]

Tsui, V. et al. A new regulatory switch in a JAK protein kinase. Proteins 79, 393–401 (2011). 10.1002/prot.22889

[30]

A Mathematical Theory of Communication

C. E. Shannon

Bell System Technical Journal 1948 10.1002/j.1538-7305.1948.tb01338.x

[31]

Gould, A. E. et al. Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors. J. Med. Chem. 54, 1836–1846 (2011). 10.1021/jm101479y

[32]

Pritchard, J. P., Lauffenburger, D. A. & Hemann, M. T. Understanding resistance to combination chemotherapy. Drug Resist Updat. 15, 249–257 (2012). 10.1016/j.drup.2012.10.003

[33]

Panjarian, S., Iacob, R. E., Chen, S., Engen, J. R. & Smithgall, T. E. Structure and Dynamic Regulation of Abl Kinases. J. Biol. Chem. 288, 5443–5450 (2013). 10.1074/jbc.r112.438382

[34]

Tanneeru, K. & Guruprasad, L. Ponatinib Is a Pan-BCR-ABL Kinase Inhibitor: MD Simulations and SIE Study. PLoS ONE 8, e78556 (2013). 10.1371/journal.pone.0078556

[35]

Guillermo Paez, J. et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science 304, 1497–1500 (2004). 10.1126/science.1099314

[36]

Kobayashi, S. et al. EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib. N Engl J Med 352, 786–792 (2005). 10.1056/nejmoa044238

[37]

Dowell, J. E. & Minna, J. D. Chasing Mutations in the Epidermal Growth Factor in Lung Cancer. N Engl J Med 352, 830–832 (2005). 10.1056/nejme058033

[38]

Tang, Z. et al. Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity. Oncogene 28, 518–33 (2009). 10.1038/onc.2008.411

[39]

Eisenstein, M. Foundation medicine. Nat Biotech. 30, 14 (2012). 10.1038/nbt0112-14

[40]

Liu, Y. & Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2, 358–364 (2006). 10.1038/nchembio799

[41]

The Structural Basis for Control of Eukaryotic Protein Kinases

Jane A. Endicott, Martin E.M. Noble, LOUISE N. JOHNSON

Annual Review of Biochemistry 2012 10.1146/annurev-biochem-052410-090317

[42]

Barabási, A.-L. Scale-Free Networks: A Decade and Beyond. Science 325, 412–413 (2009). 10.1126/science.1173299

[43]

Authoritative sources in a hyperlinked environment

Jon M. Kleinberg

Journal of the ACM 1999 10.1145/324133.324140

[44]

Hudelson, M., Mooney, B. L. & Clark, A. E. Determining polyhedral arrangements of atoms using PageRank. J. Math. Chem. 50, 2342–2350 (2012). 10.1007/s10910-012-0033-7

[45]

Yang, Z., Májek, P. & Bahar, I. Allosteric Transitions of Supramolecular Systems Explored by Network Models: Application to Chaperonin GroEL. PLoS Comp. Biol. 10.1371/journal.pcbi.1000360 (2009). 10.1371/journal.pcbi.1000360

[46]

Tominaga, Y. & Jorgensen, W. L. General model for estimation of the inhibition of protein kinases using Monte Carlo simulations. J Med Chem. 47, 2534–49 (2004). 10.1021/jm0304358

[47]

McGillick, B. E., Balius, T. E., Mukherjee, S. & Rizzo, R. C. Origins of resistance to the HIVgp41 viral entry inhibitor T20. Biochem. J. 49, 3575–92 (2010). 10.1021/bi901915g

Metrics

6

Citations

47

References

Details

Published: Dec 03, 2014
Vol/Issue: 4(1)
License: View

Authors

Cite This Article

Venky Soundararajan, Murali Aravamudan (2014). Global connectivity of hub residues in Oncoprotein structures encodes genetic factors dictating personalized drug response to targeted Cancer therapy. Scientific Reports, 4(1). https://doi.org/10.1038/srep07294

Global connectivity of hub residues in Oncoprotein structures encodes genetic factors dictating personalized drug response to targeted Cancer therapy

You May Also Like